Systemic treatment of hepatocellular carcinoma: Dawn of a new era?

Annals of Surgical Oncology

Volumn 17, Issue 5, 2010, Pages 1247-1256

  Zhu, Andrew X ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALPHA INTERFERON; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB ALANINATE; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PAZOPANIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; UNINDEXED DRUG; VATALANIB;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; INFECTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VALIDATION PROCESS; VOMITING;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77952044952     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0975-6     Document Type: Review

References (73)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
2. SR Kim M Kudo O Hino, et al. 2008 Epidemiology of hepatocellular carcinoma in Japan and Korea. A review Oncology 75 Suppl 1 13 16 10.1159/000173419 19092267
3. SF Altekruse KA McGlynn ME Reichman 2009 Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 1485 1491 10.1200/JCO.2008.20.7753 19224838
4. HB El-Serag KL Rudolph 2007 Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis Gastroenterology 132 2557 2576 10.1053/j.gastro.2007. 04.061 1:CAS:528:DC%2BD2sXnvFOgsrw%3D 17570226 (Pubitemid 46890874)
5. AX Zhu 2006 Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist 11 790 800 10.1634/theoncologist.11-7-790 1:CAS:528:DC%2BD28XhtFKlsb7J 16880238 (Pubitemid 44157567)
6. C Clavière JP Bronowicki H Hudziak MA Bigard P Gaucher 1998 Roles of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma Gastroneterol Clin Biol 22 73 86 (Pubitemid 28112708)
7. A Francavilla L Polimeno A DiLeo, et al. 1989 The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro Hepatology 9 614 620 10.1002/hep.1840090417 1:CAS:528:DyaL1MXhs1Kgt74%3D 2784403 (Pubitemid 19094587)
8. SY Jiang RY Shyu MY Yeh VC Jordan 1995 Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism J Hepatol 23 712 719 10.1016/0168-8278(95)80038-7 1:CAS:528:DyaK28Xht1Cmu7k%3D 8750171 (Pubitemid 26014856)
9. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet. 1998;352:17-20. (Pubitemid 28306560)
10. PK Chow BC Tai CK Tan, et al. 2002 High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial Hepatology 36 1221 1226 10.1053/jhep.2002.36824 1:CAS:528: DC%2BD38XovFaktrw%3D 12395333 (Pubitemid 35253439)
11. CL Liu ST Fan IO Ng, et al. 2000 Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study Am J Gastroenterol 95 218 222 10.1111/j.1572-0241.2000.01688.x 1:CAS:528:DC%2BD3cXptlemug%3D%3D 10638587
12. EK Manesis G Giannoulis P Zoumboulis, et al. 1995 Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial Hepatology 21 1535 1542 1:STN:280:DyaK2M3os1WgtA%3D%3D 7768497
13. S Riestra M Rodriguez M Delgado, et al. 1998 Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma J Clin Gastroenterol 26 200 203 10.1097/00004836-199804000-00010 1:STN:280:DyaK1c3mtV2qtA%3D%3D 9600369 (Pubitemid 28211364)
14. C Grimaldi H Bleiberg F Gay, et al. 1998 Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial J Clin Oncol 16 411 417 1:CAS:528:DyaK1cXhtFSht7g%3D 9469323 (Pubitemid 28135581)
15. E Sciarrino RG Simonetti S Le Moli L Pagliaro 1985 Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients Cancer 56 2751 2755 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O 1:STN:280:DyaL28%2FislKktg%3D%3D 2413981 (Pubitemid 16216280)
16. SR Nerenstone DC Ihde MA Friedman 1988 Clinical trials in primary hepatocellular carcinoma: Current status and future directions Cancer Treat Rev 15 1 31 10.1016/0305-7372(88)90007-2 1:STN:280:DyaL1c7psVeltw%3D%3D 2834053
17. TW Leung YZ Patt WY Lau, et al. 1999 Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1676 1681 1:CAS:528:DyaK1MXltVCqsbc%3D 10430068
18. W Yeo TS Mok B Zee, et al. 2005 A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 1532 1538 1:CAS:528:DC%2BD2MXhtFCjtb7O 16234567 (Pubitemid 41631953)
19. M Huang G Liu 1999 The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line Cancer Lett 135 97 105 10.1016/S0304-3835(98)00280-8 1:CAS:528:DyaK1MXht1Smtrc%3D 10077227
20. A Kato M Miyazaki S Ambiru, et al. 2001 Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection J Surg Oncol 78 110 115 10.1002/jso.1129 1:STN:280:DC%2BD3Mrjt1Gqtg%3D%3D 11579388 (Pubitemid 32906122)
21. MT Kuo JY Zhao LD Teeter, et al. 1992 Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice Cell Growth Differ 3 531 540 1:CAS:528:DyaK3sXmt1ejtr4%3D 1356418
22. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D 15466206 (Pubitemid 39331023)
23. L Liu Y Cao C Chen, et al. 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858 10.1158/0008-5472.CAN-06- 1377 1:CAS:528:DC%2BD28Xhtlagu73F 17178882 (Pubitemid 46094197)
24. GK Abou-Alfa L Schwartz S Ricci, et al. 2006 Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 4293 4300 10.1200/JCO.2005.01.3441 1:CAS:528:DC%2BD28XhtVGju7jE 16908937 (Pubitemid 46630787)
25. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
26. AL Cheng YK Kang Z Chen, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25 34 10.1016/S1470-2045(08)70285-7 1:CAS:528:DC%2BD1cXhsFChtbnM 19095497
27. Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S + D) versus placebo plus doxorubicin (P + D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) (abstract 128), Orlando, FL. Presented at 2008 gastrointestinal cancers symposium.
28. L Messerini L Novelli CE Comin 2004 Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma J Clin Pathol 57 867 871 10.1136/jcp.2003. 015784 1:STN:280:DC%2BD2cznslSqtg%3D%3D 15280410 (Pubitemid 39061438)
29. H Miura T Miyazaki M Kuroda, et al. 1997 Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma J Hepatol 27 854 861 10.1016/S0168-8278(97)80323-6 1:STN:280:DyaK1c%2Fktlehsw%3D%3D 9382973 (Pubitemid 27454829)
30. R Yamaguchi H Yano A Iemura, et al. 1998 Expression of vascular endothelial growth factor in human hepatocellular carcinoma Hepatology 28 68 77 10.1002/hep.510280111 1:CAS:528:DyaK1cXks1aqsLo%3D 9657098 (Pubitemid 28299987)
31. R Yamaguchi H Yano Y Nakashima, et al. 2000 Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues Oncol Rep 7 725 729 1:CAS:528:DC%2BD3cXksVCjsbg%3D 10854533
32. Y Chao CP Li GY Chau, et al. 2003 Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery Ann Surg Oncol 10 355 362 10.1245/ASO.2003.10.002 12734082 (Pubitemid 40486931)
33. KS Jeng IS Sheen YC Wang, et al. 2004 Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study World J Gastroenterol 10 643 648 1:CAS:528:DC%2BD2cXjtFGrsbk%3D 14991930 (Pubitemid 38351528)
34. RT Poon JW Ho CS Tong, et al. 2004 Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma Br J Surg 91 1354 1360 10.1002/bjs.4594 1:CAS:528:DC%2BD2cXps1Kmurc%3D 15376182 (Pubitemid 39331462)
35. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy Nat Med 7 987 989 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D 11533692 (Pubitemid 32937367)
36. CG Willett Y Boucher E di Tomaso, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D 14745444 (Pubitemid 38524883)
37. AB Siegel EI Cohen A Ocean, et al. 2008 Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2992 2998 10.1200/JCO.2007.15.9947 1:CAS:528:DC%2BD1cXoslOqsL0%3D 18565886
38. D Malka C Dromain F Farace, et al. 2007 Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring J Clin Oncol 25 Suppl 4570
39. AX Zhu LS Blaszkowsky DP Ryan, et al. 2006 Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 1898 1903 10.1200/JCO.2005.04.9130 1:CAS:528:DC%2BD28XkvVajtb8%3D 16622265 (Pubitemid 46638989)
40. W Sun DG Haller K Mykulowycz, et al. 2007 Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study J Clin Oncol 25 Suppl 4574
41. C Hsu T Yang C Hsu, et al. 2007 Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study J Clin Oncol 25 Suppl 15190
42. MB Thomas JS Morris R Chadha, et al. 2009 Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 843 850 10.1200/JCO.2008.18.3301 1:CAS:528:DC%2BD1MXjs1Kntr4%3D 19139433
43. A Arora EM Scholar 2005 Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther 315 971 979 10.1124/jpet.105.084145 1:CAS:528:DC%2BD2MXhtlalur3L 16002463 (Pubitemid 41635382)
44. DB Mendel AD Laird X Xin, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485 (Pubitemid 36109749)
45. T Pawson 2002 Regulation and targets of receptor tyrosine kinases Eur J Cancer 38 Suppl 5 S3 S10 10.1016/S0959-8049(02)80597-4 12528767
46. AX Zhu DV Sahani DG Duda, et al. 2009 Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study J Clin Oncol 27 3027 3035 10.1200/JCO.2008.20.9908 1:CAS:528:DC%2BD1MXoslyisb8%3D 19470923
47. S Faivre E Raymond E Boucher, et al. 2009 Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study Lancet Oncol 10 794 800 10.1016/S1470-2045(09)70171- 8 1:CAS:528:DC%2BD1MXptlals70%3D 19586800
48. H Huynh PK Chow N Palanisamy, et al. 2008 Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma J Hepatol 49 52 60 10.1016/j.jhep.2008.02.022 1:CAS:528:DC%2BD1cXmvFels7k%3D 18490075
49. JL Raoul RS Finn YK Kang, et al. 2009 An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) J Clin Oncol 27 Suppl 4577
50. H Toh P Chen BI Carr, et al. 2009 A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis J Clin Oncol 27 Suppl 4581
51. CC Yau PJ Chen CM Curtis, et al. 2009 A phase I study of pazopanib in patients with advanced hepatocellular carcinoma J Clin Oncol 27 Suppl 3561
52. SR Wedge J Kendrew LF Hennequin, et al. 2005 AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 4389 4400 10.1158/0008-5472.CAN-04-4409 1:CAS:528:DC%2BD2MXktlSmtLs%3D 15899831 (Pubitemid 40775678)
53. Alberts SR, Morlan BW, Kim GP, et al. NCCTG phase II trial (N044 J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-interim review of toxicity (abstract 186), Orlando, FL. Presented at 2007 gastrointestinal cancers symposium.
54. JM Wood 2000 Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy Medicina (B Aires) 60 Suppl 2 41 47 1:CAS:528:DC%2BD3cXos1OgsLg%3D
55. J Drevs R Muller-Driver C Wittig, et al. 2002 PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging Cancer Res 62 4015 4022 1:CAS:528:DC%2BD38XlsV2lsLg%3D 12124335 (Pubitemid 34791068)
56. I Koch A Baron S Roberts, et al. 2007 Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (pts) with unresectable hepatocellular carcinoma (HCC) J Clin Oncol 23 Suppl 4134
57. CR Carlin D Simon J Mattison BB Knowles 1988 Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines Mol Cell Biol 8 25 34 1:CAS:528: DyaL1cXnt12rsQ%3D%3D 2827003 (Pubitemid 18015570)
58. K Harada G Shiota H Kawasaki 1999 Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma Liver 19 318 325 10.1111/j.1478-3231.1999.tb00056.x 1:CAS:528:DyaK1MXltVKgsbk%3D 10459631 (Pubitemid 29359097)
59. Y Ito T Takeda S Higashiyama, et al. 2001 Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: An immunohistochemical study Oncol Rep 8 903 907 1:STN:280:DC%2BD3Mzkslylsg%3D%3D 11410807 (Pubitemid 33758146)
60. S Kira T Nakanishi S Suemori, et al. 1997 Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma Liver 17 177 182 1:STN:280:DyaK2svktlKqtw%3D%3D 9298487 (Pubitemid 27394085)
61. A Kiss NJ Wang JP Xie SS Thorgeirsson 1997 Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas Clin Cancer Res 3 1059 1066 1:CAS:528: DyaK2sXkvFCgs7k%3D 9815784 (Pubitemid 27319751)
62. YC Yeh JF Tsai LY Chuang, et al. 1987 Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma Cancer Res 47 896 901 1:CAS:528:DyaL2sXitFWku7c%3D 2433030
63. PA Philip MR Mahoney C Allmer, et al. 2005 Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 6657 6663 10.1200/JCO.2005.14.696 1:CAS:528:DC%2BD2MXhtFWqsLbJ 16170173 (Pubitemid 46190260)
64. MB Thomas R Chadha K Glover, et al. 2007 Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 1059 1067 10.1002/cncr.22886 1:CAS:528:DC%2BD2sXhtVChs7fJ 17623837 (Pubitemid 47312872)
65. PJ O'Dwyer BJ Giantonio DE Levy, et al. 2006 Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203 J Clin Oncol 24 Suppl 4143
66. RK Ramanathan CP Belani DA Singh, et al. 2009 A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Cancer Chemother Pharmacol 64 777 783 10.1007/s00280-009-0927-7 1:CAS:528:DC%2BD1MXptFCks74%3D 19169683
67. AX Zhu K Stuart LS Blaszkowsky, et al. 2007 Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 581 589 10.1002/cncr.22829 1:CAS:528:DC%2BD2sXpt1yqu7s%3D 17583545 (Pubitemid 47106147)
68. V Gruenwald L Wilkens M Gebel, et al. 2007 A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results J Clin Oncol 25 Suppl 4598
69. S Louafi V Boige M Ducreux, et al. 2007 Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Cancer 109 1384 1390 10.1002/cncr.22532 1:CAS:528: DC%2BD2sXkslKitbw%3D 17330837 (Pubitemid 46466566)
70. BH O'Neil SA Bernard RM Goldberg, et al. 2008 Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma J Clin Oncol 26 Suppl 4604
71. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-83, 1983.e1-11.
72. L Chen HS Shiah CY Chen, et al. 2009 Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) J Clin Oncol 27 Suppl 4587
73. BH O'Neil LW Williams-Goff J Kauh, et al. 2009 A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma J Clin Oncol 27 Suppl e15574